QQQ   414.40 (-2.13%)
AAPL   165.07 (-1.18%)
MSFT   399.32 (-1.22%)
META   481.12 (-4.12%)
GOOGL   153.90 (-1.35%)
AMZN   174.24 (-2.78%)
TSLA   146.99 (-1.96%)
NVDA   769.04 (-9.17%)
AMD   146.04 (-5.83%)
NIO   3.81 (-4.75%)
BABA   69.08 (+0.29%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.18 (-5.14%)
GE   148.36 (-2.99%)
CGC   7.99 (+2.04%)
DIS   112.17 (-0.23%)
AMC   3.21 (+9.93%)
PFE   25.96 (+2.24%)
PYPL   61.86 (-0.39%)
XOM   119.87 (+1.14%)
QQQ   414.40 (-2.13%)
AAPL   165.07 (-1.18%)
MSFT   399.32 (-1.22%)
META   481.12 (-4.12%)
GOOGL   153.90 (-1.35%)
AMZN   174.24 (-2.78%)
TSLA   146.99 (-1.96%)
NVDA   769.04 (-9.17%)
AMD   146.04 (-5.83%)
NIO   3.81 (-4.75%)
BABA   69.08 (+0.29%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.18 (-5.14%)
GE   148.36 (-2.99%)
CGC   7.99 (+2.04%)
DIS   112.17 (-0.23%)
AMC   3.21 (+9.93%)
PFE   25.96 (+2.24%)
PYPL   61.86 (-0.39%)
XOM   119.87 (+1.14%)
QQQ   414.40 (-2.13%)
AAPL   165.07 (-1.18%)
MSFT   399.32 (-1.22%)
META   481.12 (-4.12%)
GOOGL   153.90 (-1.35%)
AMZN   174.24 (-2.78%)
TSLA   146.99 (-1.96%)
NVDA   769.04 (-9.17%)
AMD   146.04 (-5.83%)
NIO   3.81 (-4.75%)
BABA   69.08 (+0.29%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.18 (-5.14%)
GE   148.36 (-2.99%)
CGC   7.99 (+2.04%)
DIS   112.17 (-0.23%)
AMC   3.21 (+9.93%)
PFE   25.96 (+2.24%)
PYPL   61.86 (-0.39%)
XOM   119.87 (+1.14%)
QQQ   414.40 (-2.13%)
AAPL   165.07 (-1.18%)
MSFT   399.32 (-1.22%)
META   481.12 (-4.12%)
GOOGL   153.90 (-1.35%)
AMZN   174.24 (-2.78%)
TSLA   146.99 (-1.96%)
NVDA   769.04 (-9.17%)
AMD   146.04 (-5.83%)
NIO   3.81 (-4.75%)
BABA   69.08 (+0.29%)
T   16.48 (+0.92%)
F   12.09 (+0.25%)
MU   106.18 (-5.14%)
GE   148.36 (-2.99%)
CGC   7.99 (+2.04%)
DIS   112.17 (-0.23%)
AMC   3.21 (+9.93%)
PFE   25.96 (+2.24%)
PYPL   61.86 (-0.39%)
XOM   119.87 (+1.14%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$278.56
-0.9%
$330.76
$261.59
$473.76
$7.94B0.87201,209 shs177,882 shs
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$18.44
$18.12
$5.80
$20.96
$1.94B2.081.87 million shs8 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
-3.36%-9.89%-16.48%-8.31%-42.22%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
4.6592 of 5 stars
3.44.00.04.21.83.31.9
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
2.80
Moderate Buy$468.0068.01% Upside
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/A

Current Analyst Ratings

Latest OXB, TRIL, and BIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/3/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$400.00 ➝ $365.00
2/16/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$395.00 ➝ $420.00
2/16/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$484.00 ➝ $480.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.67B2.97$11.59 per share24.03$306.51 per share0.91
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$150K12,907.39N/AN/A$2.56 per share7.20

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
-$637.32M-$21.49N/A24.31N/A-23.86%3.90%2.77%5/7/2024 (Confirmed)
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/A

Latest OXB, TRIL, and BIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.04N/A-$2.04N/AN/AN/A  
2/15/2024Q4 2023
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.93$3.10+$0.17-$5.94$685.00 million$681.18 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
N/AN/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
0.14
5.83
4.34
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/A
19.82
19.82

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
65.24%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
87.15%

Insider Ownership

CompanyInsider Ownership
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
17.06%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
9.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
8,03028.52 million23.65 millionOptionable
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
33105.00 million95.44 millionOptionable

OXB, TRIL, and BIO Headlines

SourceHeadline
Cachet Bicycle shakes off COVIDCachet Bicycle shakes off COVID
baytoday.ca - February 25 at 12:23 PM
Rejuvenate your look with a trip to Fourth Avenue Medical AestheticsRejuvenate your look with a trip to Fourth Avenue Medical Aesthetics
chch.com - January 30 at 5:32 PM
TTI apprehends motorists for illegal removal of clamps, hunt for four others underwayTTI apprehends motorists for illegal removal of clamps, hunt for four others underway
bulawayo24.com - January 30 at 5:32 PM
BridgeBio raises $1.25bn, and other biotech financingsBridgeBio raises $1.25bn, and other biotech financings
pharmaphorum.com - January 19 at 7:18 AM
Ratio Therapeutics Raises $50M in Series B FinancingRatio Therapeutics Raises $50M in Series B Financing
precisionmedicineonline.com - January 17 at 1:39 PM
Leiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.comLeiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.com
businesswire.com - November 10 at 1:22 PM
Mirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, PredictionsMirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, Predictions
benzinga.com - November 8 at 1:30 AM
The Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast periodThe Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast period
uk.finance.yahoo.com - July 31 at 9:03 AM
Ratio Therapeutics unveils new research and development facilityRatio Therapeutics unveils new research and development facility
biopharma-reporter.com - May 15 at 10:33 AM
WHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: Can Cause Even DeathWHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death'
msn.com - April 26 at 12:18 AM
Leukemia Therapeutics Global Market Report 2023Leukemia Therapeutics Global Market Report 2023
uk.finance.yahoo.com - April 4 at 10:35 AM
Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with MerckRatio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck
finance.yahoo.com - March 28 at 9:12 AM
Trillium House, an affordable housing project in Warrenton, close to completionTrillium House, an affordable housing project in Warrenton, close to completion
dailyastorian.com - January 10 at 12:26 AM
FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular CarcinomaFDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma
nz.finance.yahoo.com - October 19 at 9:39 AM
Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer TreatmentCardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
seekingalpha.com - September 14 at 9:48 AM
Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of DirectorsZentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors
nz.finance.yahoo.com - September 12 at 7:55 AM
Pfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is NeededPfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is Needed
seekingalpha.com - August 17 at 11:07 AM
TTI reviews parking modelTTI reviews parking model
chronicle.co.zw - August 10 at 10:41 PM
TTI working round the clock to configure its systemsTTI working round the clock to configure its systems
chronicle.co.zw - August 10 at 10:41 PM
Pfizer in advanced talks to buy firm making sickle cell drugsPfizer in advanced talks to buy firm making sickle cell drugs
pmnewsnigeria.com - August 7 at 3:57 AM
10 Psychedelics CEOs To Pay Attention To In 202210 Psychedelics CEOs To Pay Attention To In 2022
markets.businessinsider.com - June 22 at 10:08 AM
Highlights from ASCO Annual Meeting 2022Highlights from ASCO Annual Meeting 2022
healio.com - June 15 at 1:37 PM
Chlormethine gel may be more effective than ointment for mycosis fungoidesChlormethine gel may be more effective than ointment for mycosis fungoides
healio.com - May 27 at 4:34 PM
Pfizer and Moderna created life-saving vaccines. So why are their stocks crumbling?Pfizer and Moderna created life-saving vaccines. So why are their stocks crumbling?
edition.cnn.com - May 20 at 2:06 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Bio-Rad Laboratories logo

Bio-Rad Laboratories

NYSE:BIO
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Trillium Therapeutics logo

Trillium Therapeutics

NASDAQ:TRIL
Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.